EMPIRI receives $500K

Excited and grateful that we received $500K from an angel investor, enabling us to move forward with our CLIA LDT certification and prototype testing for CAL, a first-in-class precision cancer diagnostic instrument.

Recent Posts

See All

Humbled and thrilled to receive our NIH/NCI R01 grant! It is a 5-year $3.07M grant for a prospective clinical trial with our E-Slice assay to predict Triple Negative Breast Cancer patient treatment re

EMPIRI has been selected to present at the Texas Life Science Forum on February 24, 2022, at the Jones Graduate School of Business, McNair Hall, Rice University, Houston, Texas. Company Showcase and I